Skip to main content
. Author manuscript; available in PMC: 2011 Jul 20.
Published in final edited form as: J Mol Cell Cardiol. 2006 Feb 3;40(3):375–383. doi: 10.1016/j.yjmcc.2005.12.004

Fig. 1.

Fig. 1

Doxorubicin decreases viability in WT cardiomyocytes in a time and dose-dependent manner. Doxorubicin 1, 10 and 50 µM was administered to neonatal cardiomyocytes obtained from WT mice. Viability was assessed at 6 and 24 h by MTT assay. At 6 h viability was decreased only at 50 µM, whereas at 24 h viability was decreased at both 1 and 10 µM and severely decreased at 50 µM. * P < 0.05 vs. baseline.